Skip to main content
. Author manuscript; available in PMC: 2023 Dec 28.
Published in final edited form as: Neurocrit Care. 2022 Nov 23;38(3):688–697. doi: 10.1007/s12028-022-01638-5

Figure 3.

Figure 3.

Phosphofructokinase-1 (PFK1) activity in microglia after inflammatory stimulation, without and with dexmedetomidine treatment. DEX treatment overall reduced PFK1 activity (mean difference = 9.126 ± 3.254 units/mL, p = 0.0127). Specifically in the DAMP-stimulated group, there was a significant reduction in PFK1 activity (mean difference = 18.79 ± 6.508 units/mL; p = 0.0421). (n = 3 for each treatment group; * - p<0.05)